Imidazole Compounds for Protecting Choroidal Endothelial Cells from Complement Injury

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Age-related macular degeneration (AMD) is a leading cause of blindness linked to heightened complement system activity.
• Accumulation of the membrane attack complex (MAC) and degeneration of macular endothelial cells (ECs) are observed in AMD-affected eyes.
• Endothelial cell death in AMD is hypothesized to result from MAC-mediated injury.

Purpose of the Study:

• To identify strategies for protecting choroidal endothelial cells (ECs) from MAC-induced cell death.
• To investigate the potential of FDA-approved small molecules as protective agents against MAC lysis.

Main Methods:

• RF/6A endothelial cells were screened with FDA-approved small molecules, followed by exposure to complement-intact human serum to quantify cell death.
• Econazole nitrate and miconazole nitrate were selected for further validation and mechanistic studies.
• Cell rescue was confirmed in primary mouse choroidal ECs.

Main Results:

• Econazole nitrate and miconazole nitrate significantly reduced lysis of choroidal ECs across a dose range of 1–100 µM.
• Drug pretreatment altered cell surface dynamics, decreasing exosome release and surface roughness while increasing endosome formation.
• These imidazole compounds demonstrated protective effects against complement-mediated endothelial cell damage.

Conclusions:

• Small molecules can effectively protect choroidal ECs from MAC-induced cell death, validating this approach for AMD.
• FDA-approved compounds like econazole and miconazole may offer a therapeutic strategy to mitigate vascular damage and slow AMD progression.